Park Ha Biological Technology Co., Ltd. (BYAH) Stock Price & Analysis
Park Ha Biological Technology Co., Ltd. (BYAH) — MoonshotScore 18/100 (Weak band), calculated Nov 18, 2026. Price $1.04 (-6.31%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Park Ha Biological Technology Co., Ltd. · BYAH
Park Ha Biological Technology Co., Ltd. is an investment holding company focused on developing skincare products under the “Park Ha” brand in China. The company operates through subsidiaries involved in direct product sales and franchise services.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Park Ha Biological Technology Co. (BYAH)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a fragile balance sheet and a full valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Full; Growth Durability: Flat; Momentum: Falling.
- quarterly revenue $1M (Q2 FY2026, quarter ended Apr 30, 2026)
- Altman Z -6.69 · Piotroski F 1
Holding back: weak fundamentals, balance-sheet strain, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 17 | Weak | |
| 18 | Weak | |
| 18 | Weak | |
| 18 | Weak | |
| 18 | Weak | |
| 18 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $1.04 |
| Change on the day | -6.31% |
| Shares traded on the day | 47.6K |
Price & events
Other perspectives
Council score for Park Ha Biological Technology Co. (BYAH): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Park Ha Biological Technology Co. (BYAH), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Park Ha Biological Technology Co., Ltd. (BYAH) is the company analyzed here. It employs 41 people. In Q2 FY2026 it reported revenue of $1M and net income of -$918,282.
What do the latest results show for Park Ha Biological Technology Co. (BYAH)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $1M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $1M | -$918,282 | -$1.52 (diluted) |
| Q1 FY2026 | $628,845 | -$459,141 | -$1.28 (diluted) |
| Q4 FY2025 | $1M | -$5M | -$60.88 (diluted) |
| Q3 FY2025 | $642,823 | -$2M | -$28.32 (diluted) |
What are the financial strengths and risks for Park Ha Biological Technology Co. (BYAH)?
Short answer · as of
What is holding it back is weak fundamentals, balance-sheet strain, weak price trend. The distress and quality screens read Altman Z -6.69 · Piotroski F 1. Trailing ratios: current ratio 3.36 · free-cash-flow yield -80.9%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -6.69 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
How does Park Ha Biological Technology Co. compare with its peers?
Short answer
Park Ha Biological Technology Co.'s score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $133.73 Nov 18, 2026 | $4.28B | 96 5-pillar Nov 18, 2026 | |
| $98.85 Nov 18, 2026 | $78.6B | 93 5-pillar Nov 18, 2026 | |
| $170.29 Nov 18, 2026 | $395B | 88 5-pillar Nov 18, 2026 | |
| $63.36 Nov 19, 2026 | $136B | 88 5-pillar Nov 18, 2026 | |
| $75.87 Nov 19, 2026 | $1.74B | 87 5-pillar Nov 18, 2026 | |
| $113.77 Nov 18, 2026 | $6.73B | 84 5-pillar Nov 18, 2026 | |
| $109.68 Nov 19, 2026 | $25.9B | 82 5-pillar Nov 18, 2026 | |
| $107.24 Nov 18, 2026 | $65.8B | 79 5-pillar Nov 18, 2026 | |
| $101.77 Nov 19, 2026 | $36.9B | 64 5-pillar Nov 18, 2026 | |
| $104.90 Nov 19, 2026 | $12.7B | 60 5-pillar Nov 18, 2026 | |
| $62.45 Nov 18, 2026 | $14.4B | 58 5-pillar Nov 18, 2026 | |
| $5.41 Nov 19, 2026 | $2.30B | 24 5-pillar Nov 18, 2026 | |
| Park Ha Biological Technology Co. (BYAH) — this page | $1.04 | — | 18 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 1
- Identified insiders
- 1
- Purchases
- 0
- Sales
- 0
- Other transactions
- 1
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BYAH in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BYAH in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About BYAH
These answers are editorial: 1 of these 9 answers is drawn from the BYAH research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for BYAH?
BYAH carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is BYAH a good stock to buy?
Stock Expert AI does not rate BYAH buy, sell or hold. Park Ha Biological Technology Co., Ltd. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the BYAH stock price today?
The last price recorded for Park Ha Biological Technology Co., Ltd. (BYAH), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for BYAH?
The main risks for Park Ha Biological Technology Co., Ltd. include intense competition in the Chinese skincare market, which is dominated by both domestic and international brands.
What are the key factors to evaluate for BYAH?
Park Ha Biological Technology Co., Ltd. (BYAH) holds a MoonshotScore in the low range. The use of Key Opinion Leaders (KOLs) and influencers in the beauty industry is highly effective in China. Not financial advice.
How frequently does BYAH data refresh on this page?
BYAH's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven BYAH's recent stock price performance?
Park Ha Biological Technology Co., Ltd. (BYAH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established brand presence in the Chinese skincare market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BYAH overvalued or undervalued right now?
Park Ha Biological Technology Co., Ltd. (BYAH) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BYAH before investing?
Before investing in Park Ha Biological Technology Co., Ltd. (BYAH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 12 figures on this page — 9 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com